Fulcrum Therapeutics, Inc.
FULC
$3.52
$0.082.33%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -18.89M | -20.33M | -19.60M | -17.30M | -17.66M |
| Total Depreciation and Amortization | 338.00K | 347.00K | 346.00K | 344.00K | 353.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 3.09M | 2.68M | 2.77M | 1.79M | 2.27M |
| Change in Net Operating Assets | -3.29M | 506.00K | 2.29M | 1.34M | -223.00K |
| Cash from Operations | -18.75M | -16.80M | -14.19M | -13.82M | -15.26M |
| Capital Expenditure | -8.00K | -159.00K | -90.00K | -65.00K | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -128.20M | -890.00K | 18.70M | 14.00M | -777.00K |
| Cash from Investing | -128.21M | -1.05M | 18.61M | 13.93M | -777.00K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 21.00K | 168.30M | 64.00K | 301.00K | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -333.00K | -- | -- | -- | -- |
| Cash from Financing | -312.00K | 168.30M | 64.00K | 301.00K | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -147.27M | 150.46M | 4.49M | 414.00K | -16.03M |